ADAGENE

Adagene to Participate in Upcoming Investor & Industry Conferences in November

November 9, 2021

SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that members of the company's management will participate virtually in the following investor and industry conferences during November 2021:

- Goldman Sachs Asia Pacific Healthcare Forum: Adagene will participate in one-on-one investor meetings during the conference November 15 - 17.
- The 8th Annual BioCentury-BayHelix China Healthcare Summit: Adagene is a presenting company at the conference November 16 19 and will participate in one-on-one meetings.
- Jefferies London Healthcare Conference: Adagene's presentation will be available to view on-demand beginning 3:00 a.m. ET / 12:00 a.m. PT on November 18. The Company will also participate in one-on-one investor meetings.
- Piper Sandler 33rd Annual Virtual Healthcare Conference: Adagene's presentation will be available to view on-demand beginning 10:00 a.m. ET / 7:00 a.m. PT on November 22. The Company will also participate in one-on-one investor meetings.

A webcast recording of the presentations will also be accessible in the <u>Investors</u> section of the company's website at https://www.adagene.com for at least 30 days.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbodyTM, and POWERbodyTM technologies, Adagene's highly differentiated pipeline features novel immunotherapy programsAdagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Internal Contact:

Ami Knoefler Adagene 650-739-9952 ir@adagene.com

External Contact:

Bruce Mackle LifeSci Advisors 646-889-1200 bmackle@lifesciadvisors.com



Source: Adagene, Inc.